Loading...
Market
Percentage increase in Agios stock price by end of 2024?
5
Resolution / Starting Odds
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Stock market data
Story
Agios' Mitapivat Achieves Positive Phase 3 Results for Thalassemia, 30.4% Response, Stock Up 20%
Jun 3, 2024, 11:24 AM
Agios Pharmaceuticals announced on Monday that its drug Mitapivat achieved positive results in a Phase 3 study for treating transfusion-dependent alpha- or beta-thalassemia in adults. The study, named ENERGIZE-T, met its primary endpoint and all key secondary endpoints. The response rate for Mitapivat was 30.4% compared to 12.6% for the placebo, showing significant reduction in the need for blood transfusions. Following the announcement, Agios' stock price surged by 20%, reaching a 2.5-year high.
View original story
Similar markets
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
Decrease • 25%
Under 50% • 25%
50% to 100% • 25%
100% to 200% • 25%
Over 200% • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Increase by over 20% • 33%
Increase by 10-20% • 33%
Increase by less than 10% • 34%
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
0-5% • 25%
6-10% • 25%
11-15% • 25%
16% or more • 25%